1. Home
  2. BLDP vs ALT Comparison

BLDP vs ALT Comparison

Compare BLDP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ballard Power Systems Inc.

BLDP

Ballard Power Systems Inc.

N/A

Current Price

$1.58

Market Cap

657.3M

Sector

Energy

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$2.04

Market Cap

573.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLDP
ALT
Founded
1979
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
657.3M
573.8M
IPO Year
2009
2005

Fundamental Metrics

Financial Performance
Metric
BLDP
ALT
Price
$1.58
$2.04
Analyst Decision
Hold
Strong Buy
Analyst Count
11
10
Target Price
$3.38
★ $17.11
AVG Volume (30 Days)
2.3M
★ 3.3M
Earning Date
11-16-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.37
EPS
★ N/A
N/A
Revenue
N/A
★ $41,000.00
Revenue This Year
$14.39
N/A
Revenue Next Year
$38.94
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 105.00
52 Week Low
$1.43
$2.00
52 Week High
$6.57
$6.44

Technical Indicators

Market Signals
Indicator
BLDP
ALT
Relative Strength Index (RSI) 34.29 25.35
Support Level N/A N/A
Resistance Level $2.25 $3.35
Average True Range (ATR) 0.08 0.13
MACD 0.02 -0.00
Stochastic Oscillator 36.25 6.14

Price Performance

Historical Comparison
BLDP
ALT

About BLDP Ballard Power Systems Inc.

Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: